Trials / Sponsors / Caribou Biosciences, Inc.
Caribou Biosciences, Inc.
Industry · 5 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Withdrawn | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosu Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus | Phase 1 | 2027-12-01 |
| Terminated | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leuk Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | 2024-02-08 |
| Recruiting | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma | Phase 1 | 2023-02-06 |
| Enrolling By Invitation | Long-Term Follow-up Study Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | — | 2022-03-16 |
| Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANT Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 | 2021-05-26 |